Sol-Gel Technologies, Ltd. has announced a product purchase agreement with Mayne Pharma Group that will provide the company with $16 million in two installments during 2025, enhancing its cash ...

Sol-Gel Technologies, Ltd., a clinical-stage dermatology company, reported financial results for the first quarter of 2025, with total revenue reaching $1 million, up from $0.5 million in the same ...

About Sol-Gel Technologies Sol-Gel Technologies, Ltd. is a dermatology company focused on identifying, developing and commercializing or partnering drug products for the treatment of skin diseases.

About Sol-Gel Technologies Sol-Gel Technologies, Ltd. is a dermatology company focused on identifying, developing, and commercializing or partnering drug products to treat skin diseases.

Sol-Gel Technologies won FDA approval for a drug for the skin disease rosacea that applies its microencapsulation technology to benzoyl peroxide. Galderma will handle US commercialization.

When the gel melted, that is, was converted to sol, the steel ball began to move downward. The gel-melting temperature was determined by the method of Takahashi et al. 19 FT-IR spectroscopy ...

About Sol-Gel Technologies Ltd. Sol-Gel Technologies Ltd. operates as a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical ...

Sol-Gel was founded in 1997 by Prof. David Avnir of the Hebrew University of Jerusalem and by Dr. Alon Seri-Levy, based on breakthrough technology developed by Prof. Avnir.

Sol-Gel also expects to enter the cosmetics market with its glass bead technology and is targeting the $1.2 billion anti-acne market with a method to provide a safer acne treatment. The company plans ...